With a steadily increasing complexity and a plethora of opportunities, a consensus is needed to assure better comparability, for example, homogenizing inclusion criteria, exclusion criteria, risk stratification (most noteworthy, the impact of smoking), staging, and diagnosis of an HPV-driven tumor, replacing the single p16-immunohistochemistry test with a combination of direct HPV tests or including more advanced molecular methods that better assist in stratifying patients at low risk for locoregional or distant recurrence. Here, CDKN2A is linked to neoplasm.